PROK - ProKidney Corp.
ProKidney Corp. , a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
As of May 14, 2026: spot at $1.70, ATM IV 170.8%, max pain $2.00, net GEX $3.8K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $506.7M
- Beta
- 1.75
- 52-Week Range
- 0.54-7.13
- CEO
- Bruce Culleton
- Employees
- 204
- IPO Date
- Jun 30, 2021
- Exchange
- NASDAQ
What PROK Looks Like to Options Traders Today
IV rank of 33.7% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($3.8K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.399) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The PROK overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked PROK overview questions
- What is PROK?
- PROK is the ticker symbol for ProKidney Corp., a listed security. ProKidney Corp. , a clinical-stage biotechnology, engages in developing cellular therapy candidates. Listed on NASDAQ. PROK is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the PROK options snapshot look like today?
- As of May 14, 2026, the PROK options snapshot shows spot at $1.70, ATM IV 170.8%, IV rank 33.7%, max pain $2.00, net GEX $3.8K, expected move 48.97%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are PROK's key statistics?
- ProKidney Corp. (PROK) carries a market capitalization of $506.7M, beta of 1.75 relative to the broader market, 52-week range of 0.54-7.13. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does PROK belong to?
- ProKidney Corp. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare PROK's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the PROK data on this page?
- The options snapshot above is dated May 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).